GSK Pursues Futura Medical's OTC Topical NSAID Under Development
This article was originally published in The Tan Sheet
GlaxoSmithKline's relationship with Futura Medical is on again as the pharmaceutical giant agrees to fund development of Futura's novel topical pain reliever TPR100
You may also be interested in...
GlaxoSmithKline further expands its rapidly growing consumer health care business by acquiring exclusive marketing rights to two cold sore treatments in a week, just months after announcing a third deal in the category
FDA's initiative to remove unapproved new drugs from the market extends to topical ibuprofen products as the agency warns eight firms about lotions containing the common nonprescription ingredient
GlaxoSmithKline will seed its growth in emerging markets with OTC drugs and other nonprescription products, according to Chris Viehbacher, the firm's North American Pharmaceuticals division president